Table 3 Long-term efficacy results for patients with investigator-defined total spinal ankylosis or Stage V radiographic criteria*
Response variableInvestigator-defined TSAStage V TSA
Total duration of adalimumab exposureTotal duration of adalimumab exposure
1 year (n = 11), (%)2 years (n = 8), (%)1 year (n = 8), (%)2 years (n = 5), (%)
ASAS 5/654.537.537.520.0
ASAS partial remission9.1012.50
BASDAI 5045.562.550.060.0
  • ASAS, ASsessment in Ankylosing Spondylitis International Working Group criteria for improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; TSA, total spinal ankylosis.

  • *All data are based on observed efficacy analyses.